Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

NCT07847073 is registered in ClinicalTrials.gov with Brett King as lead sponsor.

NCT NCT07847073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07847073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Lead sponsor
Brett King
Phase
Phase 4
Overall status
Recruiting
Start date
October 31, 2026
Completion date
January 31, 2028
Enrollment
13 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, open angle glaucoma (oag)